CFDA Publishes Illegal Pharma, Device Advertising Report
This article was originally published in PharmAsia News
China FDA’s national report on illicit drug and medical device advertisements for the first quarter of 2013 showed investigations conducted on 36,747 ads for drugs, and 3,828 for devices, resulting in 37 advertising approval codes being revoked and 76 sales suspensions.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.